DTMTM Spinal Cord Stimulation Using the Medtronic IntellisTM Platform Shows Superior Back Pain Relief Compared to Conventional SCS Therapy in an RCT
(WorldNews Entertainment)

At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Relief of at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1 DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced three-month results from a large, multicenter randomized controlled trial (RCT) showing statistically significant (p=0.0009) and superior back pain relief with Differential Target Multiplexed (DTMTM) Spinal Cord Stimulation (SCS) compared to conventional SCS. Both arms used the Medtronic IntellisTM platform. Three-month results showed 80% of patients with chronic back pain treated with DTM reported at least 50% pain relief, compared with 51% of patients...